ArticleScience advances2022
Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Advanced Drug Delivery in Pediatric Neurology: Developmental Barriers, Nanocarrier Strategies, and Translational Challenges.International journal of molecular sciences · 2026Review
- Epilepsy: Molecular Pathogenesis and Emerging Therapies.MedComm · 2026Review
- Iron single-atom nanozyme-mediated laser interstitial thermal therapy and anti-inflammatory effect for epilepsy.Materials today. Bio · 2026Article
- Materials and System Design for Self-Decision Bioelectronic Systems.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- A microfluidic biomimetic system from the blood-brain barrier to activated microglia towards anti-Mesial Temporal Lobe Epilepsy drug screening.Analytical and bioanalytical chemistry · 2026Article
- Epileptogenic zone-targeting nanoparticle drug delivery system for antiseizure medication.Materials today. Bio · 2025Article
- Cascade-targeting copper homeostasis nano-regulators for mild-photothermal boosted cuproptosis/ferroptosis mediated breast cancer therapy.Journal of nanobiotechnology · 2025Article
- IL-1β and HMGB1 in Epileptogenesis: Recent Advances and Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Blood‑brain barrier dysfunction in epilepsy: Mechanisms, therapeutic strategies and future orientation (Review).International journal of molecular medicine · 2025Review
- Review
- Photothermal Release by Melanin-like Nanoparticles: Biomedical Applications.Journal of functional biomaterials · 2025Review
- Biosynthesized nanoparticles of Tibetan medicine mercuric sulfide preparation to promote endocytosis and realize drug crossing through blood brain barrier.Journal of nanobiotechnology · 2025Article
- Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies.Pharmaceutics · 2025Review
- Suppression of epileptic seizures by transcranial activation of KNature communications · 2025Article
- A Revolutionary Approach for Combating Efflux Transporter-mediated Resistant Epilepsy: Advanced Drug Delivery Systems.Current pharmaceutical design · 2025Review
- Phenolic-enabled nanotechnology: a new strategy for central nervous system disease therapy.Journal of Zhejiang University. Science. B · 2024Review
- Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood-Brain Barrier Crossing Ability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Review
- Advancements in the application of nanotechnology for the management of epileptic seizures.Acta epileptologica · 2024Review
- Antiepileptic drug-loaded and multifunctional iron oxide@silica@gelatin nanoparticles for acid-triggered drug delivery.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term pharmacotherapy, serving as the main therapeutic approach for epilepsy prophylaxis, has suffered from limited efficacy and potential side effects because of the blood-brain barrier (BBB) and untimely medication. Here, we reported a nanoengineered drug delivery system for synergistic brain-targeting delivery and on-demand drug release of antiepileptic drugs (AEDs). The dopamine-pyrrole hybrid system can improve delivery efficiency through a combination of receptor-mediated transcytosis and BBB disruption–enabled transport induced by photothermal conversion of near-infrared light. Incorporation of polydopamine endowed the delivery system with enhanced conductivity and sensitivity, giving sustained (2 hours) and rapid (30 s) drug release in response to epileptiform discharges. Acute, continuous, and spontaneous seizure models validated that the delivery system could inhibit seizures upon epileptiform abnormalities, treated by one-fifth of the conventional dosage. Complemented with satisfactory biosafety results, this “smart” modality is promising to be an effective and safe strategy to improve the therapeutic index of AEDs for epilepsy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.